{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:57:49Z","timestamp":1793923069295,"version":"4.8.0"},"reference-count":57,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Janus kinase (JAK) inhibitors are highly effective medications for several immune-mediated inflammatory diseases (IMIDs). However, safety concerns have led to regulatory restrictions.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare the risk of adverse events with JAK inhibitors vs tumor necrosis factor (TNF) antagonists in patients with IMIDs in head-to-head comparative effectiveness studies.<\/jats:p><\/jats:sec>Data Sources<\/jats:title>For this systematic review and meta-analysis, the Ovid Medline, Ovid EMBASE, and Web of Science databases were searched from inception to June 25, 2025.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>Head-to-head comparative effectiveness studies of adults (aged \u226518 years) with IMIDs (including rheumatoid arthritis, inflammatory bowel disease, psoriasis or psoriatic arthritis, or spondyloarthropathy) treated with either JAK inhibitors or TNF antagonists were included. Randomized clinical trials, noncomparative observational studies, studies not reporting outcomes of interest or focused solely on specific safety events, and studies with a sample size of less than 500 were excluded. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline was followed.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>Four investigators independently, and in pairs, abstracted data from included studies. A random-effects meta-analysis was conducted to obtain incidence rates (IRs) and hazard ratios (HRs) for JAK inhibitors vs TNF antagonists for each safety outcome (serious infections, malignant neoplasms, major cardiovascular events [MACEs], or venous thromboembolism [VTE]), adjusting for key confounding variables. Heterogeneity was quantified using the I<\/jats:italic>2<\/jats:sup> statistic. Risk of bias was assessed by 2 investigators independently using the Newcastle-Ottawa Scale.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was risk of serious infections, malignant neoplasms, MACEs, or VTE.<\/jats:p><\/jats:sec>Results<\/jats:title>This meta-analysis of 42 studies with low to moderate risk of bias included 813\u202f881 patients (median age, 55.7 years [IQR, 53.0-59.0 years] for JAK inhibitor users and 51.5 years [IQR, 42.7-57.4 years] for TNF antagonist users; 76.5% female). For patients using JAK inhibitors vs TNF antagonists, there was no significant difference in risk of serious infections (IR, 3.79 [95% CI, 2.85-5.05] vs 3.03 [2.32-3.95] per 100 person-years; pooled HR, 1.05 [95% CI, 0.97-1.13]), malignant neoplasms (IR, 1.00 [0.77-1.31] vs 0.94 [0.72-1.22] per 100 person-years; pooled HR, 1.02 [0.90-1.16]), or MACEs (IR, 0.72 [0.56-0.92] vs 0.66 [0.49-0.89] per 100 person-years; pooled HR, 0.91 [0.80-1.04]), with minimal to moderate heterogeneity. There was a slightly higher risk of VTE with JAK inhibitors vs TNF antagonists (IR, 0.57 [95% CI, 0.40-0.82] vs 0.52 [0.37-0.73] per 100 person-years; pooled HR, 1.26 [95% CI, 1.03-1.54]). Effect estimates were largely stable across subgroups and on meta-regression.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The head-to-head studies in this systematic review and meta-analysis did not identify any meaningful difference in the risk of serious infections, malignant neoplasms, or MACEs with JAK inhibitor vs TNF antagonist use across all IMIDs, with low overall incidence. JAK inhibitor use was associated with a slightly higher risk of VTE. Further research, especially long-term studies, is needed to fully elucidate the safety of JAK inhibitors and TNF antagonists across diverse populations and optimize clinical use.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.31204","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:00:25Z","timestamp":1757516425000},"page":"e2531204","source":"Crossref","is-referenced-by-count":44,"title":["Comparative Safety of JAK Inhibitors vs TNF Antagonists in Immune-Mediated Inflammatory Diseases"],"prefix":"10.1001","volume":"8","author":[{"given":"Virginia","family":"Solitano","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Gastrointestinal Endoscopy, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy"},{"name":"Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla"},{"name":"Department of Medicine, Indira Gandhi Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla"},{"name":"Division of Gastroenterology, Department of Internal Medicine, Yeouido St Mary\u2019s Hospital College of Medicine, The Catholic University of Korea, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Gaikwad","sequence":"additional","affiliation":[{"name":"California Northstate University School of Medicine, Elk Grove"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Hung","family":"Yeh","sequence":"additional","affiliation":[{"name":"Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Facciorusso","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abha G.","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Autoimmunity, and Inflammation, Department of Medicine, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin N.","family":"Ananthakrishnan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Massachusetts General Hospital, Boston"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada"},{"name":"Division of Gastroenterology, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla"},{"name":"Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"issue":"7","key":"zoi250882r1","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"issue":"4","key":"zoi250882r2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis.","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250882r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103504","article-title":"Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: an international appropriateness study.","volume":"23","author":"Solitano","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"24","key":"zoi250882r7","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/sim.1009","article-title":"A refined method for the meta-analysis of controlled clinical trials with binary outcome.","volume":"20","author":"Hartung","year":"2001","journal-title":"Stat Med"},{"issue":"11","key":"zoi250882r8","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"7414","key":"zoi250882r9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7304","key":"zoi250882r10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis.","volume":"323","author":"Sterne","year":"2001","journal-title":"BMJ"},{"issue":"2","key":"zoi250882r11","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/S2665-9913(19)30137-7","article-title":"Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study.","volume":"2","author":"Pawar","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"zoi250882r12","first-page":"201","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases.","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther"},{"key":"zoi250882r13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1165711","article-title":"Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study.","volume":"14","author":"Song","year":"2023","journal-title":"Front Pharmacol"},{"key":"zoi250882r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152214","article-title":"Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: a nationwide population-based study.","volume":"61","author":"Song","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"zoi250882r15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13075-018-1539-6","article-title":"Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.","volume":"20","author":"de \u00c1vila Machado","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"zoi250882r16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/rmdopen-2023-003630","article-title":"Comparative cardiovascular safety with Janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.","volume":"9","author":"Bower","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"zoi250882r17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13075-023-03111-w","article-title":"Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.","volume":"25","author":"Choi","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"zoi250882r18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/rmdopen-2023-003885","article-title":"Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database.","volume":"10","author":"Sakai","year":"2024","journal-title":"RMD Open"},{"issue":"4","key":"zoi250882r19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/rmdopen-2023-003489","article-title":"Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT Register.","volume":"9","author":"Meissner","year":"2023","journal-title":"RMD Open"},{"issue":"9","key":"zoi250882r20","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1136\/ard-2023-225271","article-title":"Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.","volume":"83","author":"Hern\u00e1ndez-Cruz","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"zoi250882r21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.","volume":"82","author":"Molander","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"zoi250882r22","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1007\/s10620-022-07404-z","article-title":"Comparative risk of thrombotic and cardiovascular events with tofacitinib and anti-TNF agents in patients with inflammatory bowel diseases.","volume":"67","author":"Kochar","year":"2022","journal-title":"Dig Dis Sci"},{"issue":"2","key":"zoi250882r23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/rmdopen-2022-002614","article-title":"Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study.","volume":"8","author":"Song","year":"2022","journal-title":"RMD Open"},{"issue":"5","key":"zoi250882r24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3899\/jrheum.200265","article-title":"The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis.","volume":"48","author":"Ozen","year":"2021","journal-title":"J Rheumatol"},{"key":"zoi250882r25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1370661","article-title":"Risk of dyslipidemia and major adverse cardiac events with tofacitinib versus adalimumab in rheumatoid arthritis: a real-world cohort study from 7580 patients.","volume":"15","author":"Ma","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"zoi250882r26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/rheumatology\/kead163","article-title":"Cancer risk in patients with rheumatoid arthritis treated with Janus kinase inhibitors: a nationwide Danish register-based cohort study.","volume":"63","author":"Westermann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"zoi250882r27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/joim.13681","article-title":"Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: a multi-centre cohort study.","volume":"294","author":"Tong","year":"2023","journal-title":"J Intern Med"},{"issue":"2","key":"zoi250882r28","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/rheumatology\/kead198","article-title":"Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry.","volume":"63","author":"Mok","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"zoi250882r29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/rmdopen-2023-003865","article-title":"Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS).","volume":"10","author":"Bastard","year":"2024","journal-title":"RMD Open"},{"issue":"10","key":"zoi250882r30","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.cgh.2022.01.013","article-title":"Risk of infections with ustekinumab and tofacitinib compared to tumor necrosis factor a antagonists in inflammatory bowel diseases.","volume":"20","author":"Cheng","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"zoi250882r31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/ard-2022-223762","article-title":"Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.","volume":"82","author":"Frisell","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"zoi250882r32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"zoi250882r33","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) study.","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"zoi250882r34","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/ard-2022-223636","article-title":"Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.","volume":"82","author":"Huss","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"zoi250882r35","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/rheumatology\/keab570","article-title":"Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.","volume":"61","author":"Huss","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"zoi250882r36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr2.11232","article-title":"Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry.","volume":"3","author":"Kremer","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"zoi250882r37","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2023045","article-title":"Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.","volume":"45","author":"Min","year":"2023","journal-title":"Epidemiol Health"},{"issue":"10","key":"zoi250882r38","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1093\/rheumatology\/kead079","article-title":"Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study.","volume":"62","author":"Uchida","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"zoi250882r39","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1093\/rheumatology\/keac226","article-title":"Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study.","volume":"61","author":"Bilgin","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"zoi250882r40","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/rheumatology\/keae109","article-title":"Comparative effectiveness of tofacitinib and tumour necrosis factor inhibitors in patients with rheumatoid arthritis in real-world practice: a prospective observational study.","volume":"64","author":"Cho","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"zoi250882r41","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/1756-185X.14414","article-title":"Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis.","volume":"25","author":"Fang","year":"2022","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"zoi250882r42","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/art.42250","article-title":"Tofacitinib and risk of malignancy: results from the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) study.","volume":"74","author":"Khosrow-Khavar","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"zoi250882r43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/rheumatology\/keab294","article-title":"Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study.","volume":"61","author":"Desai","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"zoi250882r44","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/rheumatology\/keaf096","article-title":"Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis.","volume":"64","author":"Sendaydiego","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"zoi250882r45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.46336","article-title":"Use of biologic or targeted synthetic disease-modifying antirheumatic drugs and cancer risk.","volume":"7","author":"Sendaydiego","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi250882r46","doi-asserted-by":"publisher","DOI":"10.1002\/art.43188","article-title":"Incidence of Major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK inhibitors compared with biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries.","author":"Aymon","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"zoi250882r47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.clinthera.2025.01.005","article-title":"Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis.","volume":"47","author":"Zhao","year":"2025","journal-title":"Clin Ther"},{"issue":"4","key":"zoi250882r48","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/joim.20064","article-title":"Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study.","volume":"297","author":"Cho","year":"2025","journal-title":"J Intern Med"},{"key":"zoi250882r49","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1565909","article-title":"Frailty and cardiovascular safety of JAK inhibitors versus TNF inhibitors in rheumatoid arthritis: a real-world comparative study of drug effects and patient profiles.","volume":"16","author":"Silvagni","year":"2025","journal-title":"Front Pharmacol"},{"key":"zoi250882r50","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X251321917","article-title":"Major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a nationwide, population-based cohort study.","author":"Kao","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"5","key":"zoi250882r51","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s40744-024-00700-2","article-title":"Methotrexate, tofacitinib, and biologic disease-modifying antirheumatic drug safety and effectiveness among patients with rheumatoid arthritis in Japan: CorEvitas Registry observational study.","volume":"11","author":"Tanaka","year":"2024","journal-title":"Rheumatol Ther"},{"key":"zoi250882r52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.06.041","article-title":"Comparative safety of Janus kinase inhibitors vs. tumor necrosis factor antagonists in patients with inflammatory bowel diseases.","author":"Ahuja","journal-title":"Clin Gastroenterol Hepatol"},{"key":"zoi250882r53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.12.007","article-title":"Differential efficacy of advanced therapies in inducing remission in ulcerative colitis based on prior exposure to TNF antagonists.","author":"Lee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"zoi250882r54","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"zoi250882r55","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association evidence synthesis.","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterology"},{"issue":"7","key":"zoi250882r56","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis.","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"issue":"6","key":"zoi250882r57","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1093\/rheumatology\/kez002","article-title":"Clinical significance of Janus kinase inhibitor selectivity.","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"zoi250882r3","unstructured":"Janus kinase (JAK) inhibitors: drug safety communication\u2014FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death. US Food and Drug Administration. December 2021. Accessed August 4, 2025. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk"},{"key":"zoi250882r4","unstructured":"EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. European Medicines Agency. November 11, 2022. Accessed August 4, 2025. https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders"},{"key":"zoi250882r6","unstructured":"Wells? GA, Wells? G, Shea? B, . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014. Accessed August 4, 2025. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2838681\/solitano_2025_oi_250882_1756925718.73771.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:00:27Z","timestamp":1757516427000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2838681"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.31204","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}